Brought to you by 
Silarus is third company out of Glaxo/Avalon collaboration; raises $10mm Series A round
27 Sep 2017
Executive Summary
The third company out of a potential ten to be established by GlaxoSmithKline PLC and Avalon Ventures as part of their 2013 collaboration, Silarus Therapeutics Inc. (blood diseases) launched with $10mm in Series A financing.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Silarus is third company out of Glaxo/Avalon collaboration; raises $10mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice